2-氯-4-异氰酸硝基苯 | 40397-95-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氯-4-异氰酸硝基苯
• 中文别名: 2-氯-4-硝基异氰酸苯酯；2-氯-4-硝基苯基异氰酸酯
• 英文名称: 2-chloro-1-isocyanato-4-nitrobenzene
• 英文别名: 2-Chloro-4-nitrophenyl isocyanate
• CAS: 40397-95-3
• 化学式: C₇H₃ClN₂O₃
• mdl: MFCD00037063
• 分子量: 198.565
• InChiKey: POLDSAUWRJCSOK-UHFFFAOYSA-N

物化性质

• 熔点：
  59-63 °C(lit.)
• 沸点：
  291.8±25.0 °C(Predicted)
• 密度：
  1.48±0.1 g/cm3(Predicted)
• 稳定性/保质期：
  常规情况下不会分解，也没有危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.2
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  6.1
• 危险品标志：
  Xn
• 危险类别码：
  R23/24/25,R36/37/38,R42
• 危险品运输编号：
  UN 2206 6.1/PG 3
• 海关编码：
  2929109000
• 包装等级：
  III
• 危险类别：
  6.1
• 安全说明：
  S22,S26,S36/37/39,S45
• 储存条件：
  请将密封、阴凉、干燥条件下保存。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 2-CHLORO-4-NITROPHENYL ISOCYANATE
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 40397-95-3
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Acute toxicity, Inhalation (Category 4), H332
Acute toxicity, Dermal (Category 4), H312
Skin irritation (Category 2), H315
Eye irritation (Category 2), H319
Specific target organ toxicity - single exposure (Category 3), H335
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R20/21, R25, R36/37/38
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
H301 Toxic if swallowed.
H312 + H332 Harmful in contact with skin or if inhaled
H315 Causes skin irritation.
H319 Causes serious eye irritation.
H335 May cause respiratory irritation.
Precautionary statement(s)
P261 Avoid breathing dust.
P280 Wear protective gloves/ protective clothing.
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C7H3ClN2O3
Molecular Weight : 198,57 g/mol
CAS-No. : 40397-95-3
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
2-Chloro-4-nitrophenyl isocyanate
Acute Tox. 3; Acute Tox. 4; -
Skin Irrit. 2; Eye Irrit. 2; STOT
SE 3; H301, H312 + H332,
H315, H319, H335
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
2-Chloro-4-nitrophenyl isocyanate
T, R20/21 - R25 - R36/37/38 -
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx), Hydrogen chloride gas
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Recommended storage temperature: 2 - 8 °C
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
Colour: yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing Melting point/range: 59 - 63 °C
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
Avoid moisture.
Incompatible materials
Strong oxidizing agentsStrong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available
burning sensation, Cough, wheezing, laryngitis, Shortness of breath, Headache, Nausea, Vomiting, To the
best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S.
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (2-Chloro-4-nitrophenyl isocyanate)
IATA: Toxic solid, organic, n.o.s. (2-Chloro-4-nitrophenyl isocyanate)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-氯-4-异氰酸硝基苯 在 sodium ethanolate 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 13.0h， 生成 4-(2-chloro-4-nitrophenyl)-1,2,4-triazolidine-3,5-dione
  参考文献：
  名称：

  从苯胺中新型高效合成 4-取代 1,2,4-三唑烷-3,5-二酮

  摘要：

  摘要 开发了一种以苯胺为原料制备 1,2,4-三唑烷二酮 (urazole) 的 4-取代苯基衍生物的简单有效的三步合成方法。在该方法中，苯胺衍生物与氯甲酸 4-硝基苯基酯反应生成相应的氨基甲酸酯衍生物。在第二步中，通过与氨基甲酸乙酯反应，由这些氨基甲酸酯制备氨基脲衍生物。相应氨基脲的环化反应以高产率提供了 1,2,4-三唑烷二酮。

  DOI：

  10.1080/00397910701316862
• 作为产物：
  描述：

  (4-nitrophenyl) N-(2-chloro-4-nitrophenyl)carbamate 在 三乙胺 作用下， 以 甲苯 为溶剂， 反应 8.0h， 生成 2-氯-4-异氰酸硝基苯
  参考文献：
  名称：

  从苯胺中新型高效合成 4-取代 1,2,4-三唑烷-3,5-二酮

  摘要：

  摘要 开发了一种以苯胺为原料制备 1,2,4-三唑烷二酮 (urazole) 的 4-取代苯基衍生物的简单有效的三步合成方法。在该方法中，苯胺衍生物与氯甲酸 4-硝基苯基酯反应生成相应的氨基甲酸酯衍生物。在第二步中，通过与氨基甲酸乙酯反应，由这些氨基甲酸酯制备氨基脲衍生物。相应氨基脲的环化反应以高产率提供了 1,2,4-三唑烷二酮。

  DOI：

  10.1080/00397910701316862

文献信息

• PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES
  申请人：Naddaka Vladimir

  公开号：US20070249823A1

  公开（公告）日：2007-10-25

  The present invention provides novel intermediates, which preferably include 3-substituted, alkyl 2,2-difluoro-3-hydroxy-3-(2,2-dialkyldioxolan-4-yl)-propionate derivatives, and 3,5-disubstituted-2-deoxy-2,2-difluoro-1-oxo-D-ribose derivatives. The present invention also provides processes for producing such intermediates and processes for producing gemcitabine therewith.

  本发明提供了新颖的中间体，其中包括3-取代的烷基2,2-二氟-3-羟基-3-(2,2-二烷基二氧杂环戊酮-4-基)-丙酸酯衍生物，以及3,5-二取代-2-脱氧-2,2-二氟-1-氧代-D-核糖衍生物。本发明还提供了生产这种中间体的方法以及生产吉西他滨的方法。
• Discovery of Novel Pyrazole–Quinazoline-2,4-dione Hybrids as 4-Hydroxyphenylpyruvate Dioxygenase Inhibitors
  作者：Bo He、Feng-Xu Wu、Liang-Kun Yu、Lei Wu、Qiong Chen、Ge-Fei Hao、Wen-Chao Yang、Hong-Yan Lin、Guang-Fu Yang

  DOI：10.1021/acs.jafc.0c00051

  日期：2020.5.6

  4-Hydroxyphenylpyruvate dioxygenase (HPPD, EC 1.13.11.27) has been identified as one of the most significant targets in herbicide discovery for resistant weed control. In a continuing effort to discover potent novel HPPD inhibitors, we adopted a ring-expansion strategy to design a series of novel pyrazole-quinazoline-2,4-dione hybrids based on the previously discovered pyrazole-isoindoline-1,3-dione

  4-羟基苯基丙酮酸双加氧酶（HPPD，EC 1.13.11.27）已被确定为抗除草剂发现中除草剂中最重要的目标之一。为了不断发现有效的新型HPPD抑制剂，我们采用了扩环策略，以先前发现的吡唑-异吲哚啉-1,3-二酮骨架为基础，设计了一系列新型的吡唑-喹唑啉-2,4-二酮杂化物。一种化合物3-（2-氯苯基）-6-（5-羟基-1,3-二甲基-1H-吡唑-4-羰基）-1,5-二甲基喹唑啉-2,4（1H，3H）-二酮（ 9bj）显示出对AtHPPD的出色效价，IC50值为84 nM，比吡草磺酚（IC50 = 1359 nM）高约16倍，而对甲基磺草酮（IC50 = 226 nM）则高2.7倍。此外，AtHPPD-9bj复合物（PDB ID 6LGT）的共晶体结构的分辨度为1.75。与现有的HPPD抑制剂相似，化合物9bj与金属离子形成双齿螯合相互作用，与Phe381和Phe424形成π-π堆积相互
• Design, Synthesis and Discovery of <i>N,N’</i> ‐Carbazoyl‐aryl‐urea Inhibitors of Zika NS5 Methyltransferase and Virus Replication
  作者：Sharon Spizzichino、Giulio Mattedi、Kate Lauder、Coralie Valle、Wahiba Aouadi、Bruno Canard、Etienne Decroly、Suzanne J. F. Kaptein、Johan Neyts、Carl Graham、Zakary Sule、David J. Barlow、Romano Silvestri、Daniele Castagnolo

  DOI：10.1002/cmdc.201900533

  日期：2020.2.17

  The recent outbreaks of Zika virus (ZIKV) infection worldwide make the discovery of novel antivirals against flaviviruses a research priority. This work describes the identification of novel inhibitors of ZIKV through a structure-based virtual screening approach using the ZIKV NS5-MTase. A novel series of molecules with a carbazoyl-aryl-urea structure has been discovered and a library of analogues

  最近在全球范围内爆发的寨卡病毒（ZIKV）感染使发现针对黄病毒的新型抗病毒药物成为研究重点。这项工作描述了使用 ZIKV NS5-MTase 通过基于结构的虚拟筛选方法鉴定新型 ZIKV 抑制剂。已经发现了一系列具有咔唑基-芳基-脲结构的新型分子，并合成了类似物库。新化合物抑制 ZIKV MTase，IC50 介于 23-48 μM 之间。此外，咔唑酰基芳基脲也被证明可以在微摩尔浓度下抑制 ZIKV 复制活性。
• Synthesis and Structure–Activity Relationships of (Aryloxy)quinazoline Ureas as Novel, Potent, and Selective Vascular Endothelial Growth Factor Receptor-2 Inhibitors
  作者：Antonio Garofalo、Amaury Farce、Séverine Ravez、Amélie Lemoine、Perrine Six、Philippe Chavatte、Laurence Goossens、Patrick Depreux

  DOI：10.1021/jm2013453

  日期：2012.2.9

  site. This model was used to direct the synthesis of new compounds. A series of N-(aromatic)-N′-4-[(6,7-dimethoxyquinazolin-4-yl)oxy]phenyl}urea were identified as potent and selective inhibitors of the tyrosine kinase activity of VEGFR-2 (fetal liver kinase 1, kinase insert domain-containing receptor). An efficient route was developed that enabled the synthesis of a wide variety of analogues with substitution

  在我们不断寻找治疗增生性疾病的药物中，喹唑啉衍生物被合成并作为上皮生长因子受体和血管内皮生长因子受体2（VEGFR-2）酪氨酸激酶抑制剂进行药理评价。进行了定量构效关系分析，以合理化构效关系并预测两种蛋白质激酶的抑制剂结合谱可能基于铅化合物对接至ATP结合位点的相似程度。该模型用于指导新化合物的合成。一系列N-（芳香族）-N'-4-[（6,7-二甲氧基喹唑啉-4-基）氧基]苯基}脲被确定为VEGFR-2酪氨酸激酶活性的有效和选择性抑制剂（胎儿肝激酶1，含激酶插入结构域的受体） 。开发了一种有效的途径，该途径使得能够合成多种类似物，并在模板的多个位置上进行取代。与ATP竞争的二芳基脲的取代，提供了几种具有低纳摩尔抑制VEGFR-2酶活性的类似物。在本文中，我们描述了该系列的合成，结构-活性关系以及药理学表征。
• Quinoline and quinazoline derivatives inhibiting platelet-derived growth
  申请人：Kirin Beer Kabushiki Kaisha

  公开号：US06143764A1

  公开（公告）日：2000-11-07

  The present invention relates to novel quinoline derivatives and quinazoline derivatives represented by the following formula (I): ##STR1## [wherein R.sub.1 and R.sub.2 are each independently H or C.sub.1 -C.sub.4 -alkyl, or R.sub.1 and R.sub.2 together form C.sub.1 -C.sub.3 -alkylene, X is O, S or CH.sub.2, W is CH or N, and Q is a substituted aryl group or substituted heteroaryl group] and their pharmaceutically acceptable salts, having platelet-derived growth factor receptor autophosphorylation inhibitory activity, to pharmaceutical compositions containing these compounds, and to methods for the treatment of diseases associated with abnormal cell growth such as tumors.

  本发明涉及由以下式（I）表示的新型喹啉衍生物和喹唑啉衍生物：[其中R.sub.1和R.sub.2分别独立地为H或C.sub.1 -C.sub.4 -烷基，或R.sub.1和R.sub.2一起形成C.sub.1 -C.sub.3 -烷基，X为O、S或CH.sub.2，W为CH或N，Q为取代芳基或取代杂芳基]及其在药学上可接受的盐，具有血小板源性生长因子受体自磷酸化抑制活性，用于含有这些化合物的药物组合物，以及用于治疗与异常细胞生长（如肿瘤）相关的疾病的方法。